PLEASANTON, Calif.--(BUSINESS WIRE)--Veeva Systems (NYSE: VEEV) today announced Veeva Oncology Link, an enterprise data solution to centralize insights and intelligence on scientific leaders in oncology. Veeva Oncology Link consolidates thousands of global experts and millions of activities, including publications, clinical trials, and events, in a single, complete source of oncology data. Now medical affairs and commercial organizations can better plan and engage top industry thought leaders and create deeper relationships with the global oncology community.
Oncology is one of the largest, most diverse, and fastest-growing specialty areas in life sciences, and the ecosystem of oncology experts is equally large and complex. Information about key scientific leaders is typically managed in disparate data sources that quickly become out of date. This makes it difficult to gain an in-depth understanding of oncology expert profiles and interests.
Veeva Oncology Link provides a single, global data source to bring together unique insights on scientific leaders for the life sciences industry. Companies can better identify and reach top scientists and researchers that are key to the successful product development and launching of new cancer treatments.
Rich, up-to-date profiles provide visibility into oncology experts’ interests, affiliations, publications, trial activity, and partnership opportunities. Data is continually kept current by utilizing both data science and a team of oncology specific Veeva data stewards.
“Building valued scientific partnerships with the right experts is key to bringing oncology products to market effectively and improving patient outcomes,” said Kilian Weiss, general manager of Veeva Oncology Link. “Veeva Oncology Link provides critical market insights across all major tumor types around the world so the industry can build stronger relationships with the global oncology community.”
Veeva will host therapeutic area leaders and experts during the Oncology Forum at the Veeva European Commercial and Medical Summit on Nov. 29, 2017 in Madrid. The Forum will feature industry leaders, including Novartis, for an in-depth discussion on oncology innovation. For more information, visit veeva.com/EuropeanSummit.
Veeva Oncology Link is planned for availability in the summer of 2018.
Additional Information
For more on Veeva Oncology Link, visit: veeva.com/OncologyLink
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 550 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended
July 31, 2017. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.